Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024
The three MRAs exhibit distinct AE profiles. Hyperkalaemia and renal impairment are shared concerns, while spironolactone requires special attention to hormonal and developmental side effects. Eplerenone shows fewer androgen-related AEs, and finerenone appears safer in this regard. Further clinical studies are needed to validate these findings and inform safer prescribing practices.
Authors
- Ligang Ji
- Yifan Zheng (ORCID: https://orcid.org/0000-0002-6997-735X)
- Lu Zhang (ORCID: https://orcid.org/0000-0003-3494-6913)
- Fang Wang (ORCID: https://orcid.org/0009-0001-8433-1346)
- Xingjun Huang
- Jia Li
- Kaiyun Ji
- Xiaodong Zhuang
- Ying Ju
Institutions
- Guiyang Medical University (CN)
- Sun Yat-sen University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Michigan Center for Translational Pathology (US)
- First Affiliated Hospital of GuangXi Medical University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Shanxi Jincheng Anthracite Mining Group (China) (CN)
- Huizhou Central People's Hospital (CN)
- CM Hospital (KR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.3389/fphar.2025.1702257
- Primary Topic
- Hormonal Regulation and Hypertension
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Guangdong Provincial Hospital of Traditional Chinese Medicine